Introduction {#s1}
============

Immune checkpoint inhibitor (ICI)-based treatments that block molecules such as programmed cell death protein 1 (PD-1), PD1 ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) have emerged as powerful weapons in a growing number of cancers ([@B63]). Currently, nine ICIs have been approved for the treatment of different cancers: anti-PD-1 (nivolumab, pembrolizumab, toripalimab, sintilimab, and cemiplimab); anti-PD-L1 (atezolizumab, avelumab, and durvalumab); and anti-CTLA-4 (ipilimumab). Immune checkpoint molecules play an important role in maintaining immunological tolerance to self-antigens and preventing autoimmune disorders ([@B40]). Consequently, their blockade in cancer therapy not only promotes T cell-mediated immune destruction on tumor cells but may also facilitate autoimmune activity that affects various organ systems ([@B26]). Thus, ICIs frequently cause toxicities related to the mechanism of action that are generally referred to as immune-related adverse events (irAEs) ([@B43]).

Among these irAEs, new-onset diabetes is receiving increased attention, as more evidence suggests the recognition of diabetes-related adverse events in patients with cancers who are treated with ICIs. A marked increase in reporting diabetes has also been seen since 2017 by analyzing the World Health Organization's database of individual case safety reports ([@B70]). These observations raised concern as to whether ICI treatments could be associated with an increased risk of diabetes in patients with cancer. However, there has been no report of a meta-analysis of the incidence or risk of ICI-associated diabetes among the different ICIs in different tumor subtypes.

Given the dramatic growth in the number of clinical trials testing ICI agents and their clinical benefits in the increasing list of cancer types and negative influence on life quality caused by diabetes if not promptly recognized, we performed a meta-analysis of randomized controlled trials (RCTs) with ICIs in patients with cancer and evaluated the incidence and risks of diabetes-related adverse events compared with placebo or another therapeutic strategy.

Methods {#s2}
=======

Search Strategy and Selection Criteria {#s2_1}
--------------------------------------

Scientific literature searches were performed in three databases (PubMed, EMBASE, and Cochrane Central Register of Controlled Trials) from the inception of all searched databases to March 2019. Relevant text words and medical subject headings that consisted of terms including 'phase' and the individual drug names (details in Supporting Information [**Table S1**](#SM1){ref-type="supplementary-material"}) were searched. The search was limited to RCTs and English language. We also performed a manual search using reference lists from trials and review articles to identify any other relevant data. The ClinicalTrials.gov website was searched for RCTs that were labeled as 'completed' with available results. This meta-analysis was performed in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@B35]).

Study Selection {#s2_2}
---------------

We included RCTs that were performed in adults with cancer and compared ICI treatment to another treatment strategy. The exclusion criteria were as follows: observational and retrospective studies; studies published in a meeting abstract without published full text original articles; quality of life studies; studies with only pediatric patients; 10 or fewer patients in any group; single dosing; cost effectiveness analyses; and those that could not assess the effect of ICI, such as when the control group was a different dose of the same ICI or another type of ICI. Two authors independently screened all titles and abstracts (HM and JZ). Two of three authors reviewed and discussed the potential full text. Any disagreements were resolved by consensus with all three (JL, HM, and JZ).

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

Data from each study that met the inclusion criteria were independently extracted by two of the three authors (JL, HM, and YL). Any disagreement was resolved by consensus with all three. The retrieved data included author name, year of publication, trial characteristics (registry number, whether it was an international study, countries involved, study sites, and study phase), patient characteristics (sex, age, and performance status), the sizes of the intervention and control groups, ICI treatment, dose, and the outcomes of interest. We detected new-onset diabetes following treatment with ICIs using the following terms: hyperglycemia, diabetes mellitus (DM), type 2 diabetes (T2D), and type 1 diabetes (T1D). For data extracted from ClinicalTrials.gov, adverse events were reported as either serious or other; for data from published reports, we identified grades 3--5 as serious and grades 1--2 as other, according to Common Terminology of Clinical Adverse Events categorization. If data were available for both sources, we prioritized data from sources where the data were more complete. If a published study did not report diabetes-related adverse events, and the corresponding registry trial from ClinicalTrials.gov reported did, we included the registry report. For multiple reports of the same trial, only the most completely reported data were used. The quality of the included studies was independently assessed using the Cochrane Risk of Bias Tool. We considered all trials at unclear risk of incomplete outcome data and selective reporting bias as these studies were not designed primarily to assess adverse events.

Data Synthesis and Analysis {#s2_4}
---------------------------

The estimated event rates in the intervention group are calculated as the total number of patients with a given adverse event divided by the total number at risk. Data were transformed using the Freeman-Tukey Double Arcsine transformation to calculate event rates. This statistical analyses were performed using R statistical software (package meta, R Foundation). For risk outcome, we pooled trials and calculated odds ratios (ORs) and their associated 95% confidence intervals (CIs) in the intervention group compared with the control group based on the number of patients with a given adverse event and sample size. Given the low rates of adverse events, we used Peto's method to pool effect estimates across studies. The *I*² statistic and *P* value were used to examine heterogeneity across trials for each outcome. An *I*² statistic of 0--25%, 26--75%, and 76--100% was regarded as indicating low, moderate, and high heterogeneity, respectively. A *P* value of less than or equal to 0.05 was defined as significant heterogeneity. If a study included more than one intervention group (e.g. different doses or different types of ICI), we separately compared each intervention group with the control group, where the number of patients or events in the control group would be doubled. Sensitivity analyses were performed excluding an everolimus-controlled study, which was known to cause diabetes-related adverse events, to understand the reasons for the high likelihood of differences. We conducted subgroup analyses to examine studies according to the type of control group (chemotherapy vs. immunosuppressive drug vs. targeted therapy vs. placebo), the mode of intervention treatment (monotherapy vs. add-on therapy), and the type of ICI (PD-1 vs. PD-L1 vs. CTLA4 vs. combination of ICIs). Evidence of publication bias was assessed using Egger's and Begg's test in addition to funnel plots, and significant publication bias defined as a *P* \< 0.1. All statistical analyses were conducted with STATA, version 15.

Results {#s3}
=======

Study Search {#s3_1}
------------

Our search from the PubMed, EMBASE, and Cochrane Central Register databases yielded a total of 8,596 potentially relevant reports ([**Figure 1**](#f1){ref-type="fig"}). After screening and eligibility assessment, we retrieved 67 reports for full text screening. We also identified 117 reports with results from ClinicalTrial.gov. After our formal search, three additional large clinical trials were published. We therefore also included these three studies. After further section, a total of 52 studies (7 from the trial registry and 45 from journals) were eligible. The included articles were published (online) between August 2010 and April 2019.

![Flow diagram of study selection.](fphar-10-01453-g001){#f1}

Study Characteristics {#s3_2}
---------------------

All studies except one ([@B10]) were international multicenter studies. All studies were funded by the pharmaceutical industry, with sample sizes of the ICI intervention group ranging from 12 to 636 patients. Twenty-two were completed in patients with non-small-cell lung cancer, eight in melanoma, six in renal cell carcinoma, three in small-cell lung cancer, three in gastric and gastro esophageal junction cancer, two in head and neck squamous cell carcinoma, two in urothelial cancer, two in prostate cancer, two in breast cancer, one in colorectal cancer, and one in mesothelioma. Among these, patients in the intervention arm received nivolumab as monotherapy in ten studies, pembrolizumab in seven studies, atezolizumab in five studies, durvalumab in three studies, avelumab in one study, tremelimumab in three studies, combination therapy with anti-PD-1/PD-L1/CTLA-4 plus chemotherapy/radiotherapy in thirteen studies, combination therapy with anti-PD-1/PD-L1 plus anti-CTLA4 in three studies, combination therapy with anti-PD-1/PD-L1/CTLA-4 plus targeted therapy in seven studies, and combination therapy with ipilimumab plus vaccine in one study. All studies except one ([@B27]) had adverse event data on ClinicalTrials.gov. Key characteristics of these included trials are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of controlled trials of ICI treatment in patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT Author (year)      International study   No. of countries involved   No. of study sites   Phase          Group type    Drug                                                      Dose of ICI (mg/kg)   No. of patients   Age\            No (%) Male   Tumor type
                                                                                                                                                                                                                               Median\                       
                                                                                                                                                                                                                               (range)                       
  ---------------------- --------------------- --------------------------- -------------------- -------------- ------------- --------------------------------------------------------- --------------------- ----------------- --------------- ------------- ---------------------------
  NCT00527735\           Yes                   8                           NR                   Phase 2        CTLA4         Ipilimumab\                                               10                    113               NR              NR            NSCLC
  ([@B45])　                                                                                                                 Paclitaxel/carboplatin                                                                                                          

                                                                                                               CTLA4         Ipilimumab\                                               10                    109               NR              NR            
                                                                                                                             Paclitaxel/carboplatin                                                                                                          

                                                                                                               Control       Paclitaxel/carboplatin                                    /                     109               NR              NR            

  NCT00861614\           Yes                   26                          191                  Phase 3        CTLA4         Ipilimumab\                                               10                    399               69 (47--86)     399           Prostate cancer
  ([@B29])                                                                                                                   Radiotherapy                                                                                                                    

                                                                                                               Control       Placebo radiotherapy                                      /                     400               67.5 (45--86)   400           

  NCT01673867\           Yes                   22                          NR                   Phase 3        PD-1          Nivolumab                                                 3                     292               61 (37--84)     151 (52)      NSCLC
  ([@B6])                                                                                                                                                                                                                                                    

                                                                                                               Control       Docetaxel                                                 /                     290               64 (21--85)     168 (58)      

  NCT01642004\           Yes                   20                          NR                   Phase 3        PD-1          Nivolumab                                                 3                     135               62 (39--85)     111 (82)      NSCLC
  ([@B7])                                                                                                                                                                                                                                                    

                                                                                                               Control       Docetaxel                                                 /                     137               64 (42--84)     97 (71)       

  NCT00636168\           Yes                   19                          91                   Phase 3        CTLA4         Ipilimumab                                                10                    475               51 (20--84)     296 (62)      Melanoma
  ([@B13])                                                                                                                                                                                                                                                   

                                                                                                               Placebo       Placebo                                                   /                     476               52 (18--78)     293 (62)      

  NCT01668784\           Yes                   24                          146                  Phase 3        PD-1          Nivolumab                                                 3                     410               62 (23--88)     315 (77)      RCC　
  ([@B37])                                                                                                                                                                                                                                                   

                                                                                                               Control       Everolimus                                                /                     411               62 (18--86)     304 (74)      

  NCT01704287\           Yes                   12                          73                   Phase 2        PD-1          Pembrolizumab                                             2                     180               62 (15--87)     104 (58)      Melanoma
  ([@B49])                                                                                                                                                                                                                                                   

                                                                                                               PD-1          Pembrolizumab                                             10                    181               60 (27--89)     109 (60)      

                                                                                                               Control       Carboplatin/paclitaxel\                                   /                     179               63 (27--87)     114 (64)      
                                                                                                                             Dacarbazine\                                                                                                                    
                                                                                                                             Temozolomide                                                                                                                    

  NCT01721772\           Yes                   16                          80                   Phase 3        PD-1          Nivolumab                                                 3                     210               64 (18--86)     121 (57.6)    Melanoma
  ([@B52])                                                                                                                                                                                                                                                   

                                                                                                               Control       Dacarbazine                                               /                     208               66 (26--87)     125 (60.1)    

  NCT01721746\           Yes                   14                          90                   Phase 3        PD-1          Nivolumab                                                 3                     272               59 (23--88)     176 (65)      Melanoma
  ([@B69])                                                                                                                                                                                                                                                   

                                                                                                               Control       Dacarbazine/carboplatin/paclitaxel                        /                     133               62 (29--85)     85 (64)       

  NCT01903993\           Yes                   13                          61                   Phase 2        PD-L1         Atezolizumab                                              1,200 mg/dose         144               62 (42--82)     93 (65)       NSCLC
  ([@B16])                                                                                                                                                                                                                                                   

                                                                                                               Control       docetaxel                                                 /                     143               62 (36--84)     76 (53)       

  NCT02105636\           Yes                   15                          NR                   Phase 3        PD-1          Nivolumab                                                 3                     240               59 (29--83)     197 (82.1)    HNSCC
  ([@B17])                                                                                                                                                                                                                                                   

                                                                                                               Control       Cetuximab/methotrexate/docetaxel                          /                     121               61 (28--78)     103 (85.1)    

  NCT01905657\           Yes                   24                          202                  Phase 2/3      PD-1          Pembrolizumab                                             2                     344               63 (56--69)     212 (62)      NSCLC
  ([@B22])                                                                                                                                                                                                                                                   

                                                                                                               PD-1          Pembrolizumab                                             10                    346               63 (56--69)     213 (62)      

                                                                                                               Control       Docetaxel                                                 /                     343               62 (56--69)     209 (61)      

  NCT02039674\           Yes                   2                           26                   Phase 2        PD-1          Pembrolizumab\                                            200 mg/dose           60                62.5 (54--70)   22 (37)       NSCLC
  ([@B30])                                                                                                                   Carboplatin/pemetrexed                                                                                                          

                                                                                                               Control       Carboplatin/pemetrexed                                    /                     63                63.2 (58--70)   26 (41)       

  NCT01450761\           Yes                   34                          224                  Phase 3        CTLA4         Ipilimumab\                                               10                    478               62 (39--85)     371 (66)      SCLC　
  ([@B46])                                                                                                                   Etoposide/cisplatin/carboplatin                                                                                                 

                                                                                                               Control       Placebo\                                                  /                     476               63 (36--81)     326 (68)      
                                                                                                                             Etoposide/cisplatin/carboplatin                                                                                                 

  NCT02142738\           Yes                   16                          142                  Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           154               64.5 (33--90)   92 (59.7)     NSCLC
  ([@B47])                                                                                                                                                                                                                                                   

                                                                                                               Control       Paclitaxel/carboplatin/pemetrexed/cisplatin/gemcitabine   /                     151               66 (38--85)     95 (62.9)     

  NCT02008227\           Yes                   31                          194                  Phase 3        PD-L1         Atezolizumab                                              1,200 mg/dose         613               NR              378 (61.7)    NSCLC
  ([@B51])                                                                                                                                                                                                                                                   

                                                                                                               Control       Docetaxel                                                 /                     612               NR              379 (61.9)    

  NCT02125461\           Yes                   26                          235                  Phase 3        PD-L1         Durvalumab                                                10                    476               64 (31--84)     334 (70.2)    NSCLC
  ([@B2])                                                                                                                                                                                                                                                    

                                                                                                               Control       Placebo                                                   /                     237               64 (23--90)     166 (70)      

  NCT01057810\           Yes                   24                          NR                   Phase 3        CTLA4         Ipilimumab                                                10                    399               NR              100           Prostate cancer
  ([@B5])                                                                                                                                                                                                                                                    

                                                                                                               Control       Placebo                                                   /                     199               NR              100           

  NCT02256436\           Yes                   120                         29                   Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           270               67 (29--88)     200 (74.1)    Urothelial carcinoma
  ([@B58])                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                             

                                                                                                               Control       Paclitaxel/docetaxel/vinflunine                           /                     272               65 (26--84)     202 (74.3)    

  NCT02041533\           Yes                   26                          NR                   Phase 3        PD-1          Nivolumab                                                 3                     271               63 (32--89)     184 (68)      NSCLC
  ([@B8])                                                                                                                                                                                                                                                    

                                                                                                               Control       Gemcitabine/cisplatin Carboplatin/paclitaxel/pemetrexed                                                                         

                                                                                                                                                                                                                                                             

                                                                                                                                                                                       /                     270               65 (29--87)     148 (55)      

  NCT01285609\           Yes                   34                          233                  Phase 3        CTLA4         Ipilimumab\                                               10                    479               NR              NR            NSCLC
  ([@B20])                                                                                                                   Paclitaxel/carboplatin                                                                                                          

                                                                                                               Control       Placebo\                                                  /                     477               NR              NR            
                                                                                                                             Paclitaxel/carboplatin                                                                                                          

  NCT02267343\           Yes                   3                           49                   Phase 3        PD-1          Nivolumab                                                 3                     330               62 (54--69)     229 (69)      GEJ
  ([@B27])                                                                                                                                                                                                                                                   

                                                                                                               Control       Placebo                                                   /                     163               61 (53--68)     119 (73)      

  NCT01843374\           Yes                   19                          105                  Phase 2b       CTLA4         Tremelimumab                                              10                    382               66 (60--72)     283 (74.1)    Mesothelioma
  ([@B31])                                                                                                                                                                                                                                                   

                                                                                                               Control       Placebo                                                   /                     189               67 (61--73)     151 (79.9)    

  NCT02302807\           Yes                   29                          217                  Phase 3        PD-L1         Atezolizumab                                              1,200 mg/dose         467               67 (33--88)     357 (76)      Urothelial bladder
  ([@B44])                                                                                                                                                                                                                                                   

                                                                                                               Control       Vinflunine/paclitaxel/docetaxel                           /                     464               67 (31--84)     361 (78)      cancer

  NCT02395172\           Yes                   31                          173                  Phase 3        PD-L1         Avelumab                                                  10                    396               64 (58--69)     269 (67.9)    NSCLC
  ([@B4])                                                                                                                                                                                                                                                    

                                                                                                               Control       Docetaxel                                                 /                     396               63 (57--69)     273 (68.9)    

  NCT02362594\           Yes                   23                          123                  Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           514               54 (19--88)     324 (63)      Melanoma
  ([@B14])                                                                                                                                                                                                                                                   

                                                                                                               Control       Placebo                                                   /                     505               54 (19--83)     304 (60.2)    

  NCT02578680\           Yes                   16                          126                  Phase 3        PD-1          Pembrolizumab Pemetrexed/cisplatin                        200 mg/dose           410               65 (34--84)     254 (62)      SCLC　
  ([@B18])                                                                                                                                                                                                                                                   

                                                                                                               Control       Pemetrexed/cisplatin                                      /                     206               63.5 (34--84)   109 (52.9)    

  NCT02231749 ([@B39])   Yes                   28                          175                  Phase 3        PD-1/CTLA4    Nivolumab\                                                3\                    550               NR              NR            RCC　
                                                                                                                             ipilimumab                                                1                                                                     

                                                                                                               Control       sunitinib                                                 /                     546               NR              NR            

  NCT02775435\           Yes                   17                          137                  Phase 3        PD-1          Pembrolizumab\                                            200 mg/dose           278               65 (29--87)     220 (79.1)    NSCLC
  ([@B41])                                                                                                                   Paclitaxel/nab-paclitaxel/carboplatin                                                                                           

                                                                                                               Control       Paclitaxel/Nab-paclitaxel/Carboplatin                     /                     281               65 (36--88)     235 (83.6)    

  NCT02370498\           Yes                   30                          148                  Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           296               62.5 (54--70)   202 (68)      GEJ　
  ([@B60])                                                                                                                                                                                                                                                   

                                                                                                               Control       Pacitraxel                                                /                     296               60.0 (53--68)   208 (70)      

  NCT02252042\           Yes                   20                          97                   Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           247               60.0 (55--66)   207 (84)      HNSCC
  ([@B12])                                                                                                                                                                                                                                                   

                                                                                                               Control       Methotrexate Docetaxel/cetuximab                          /                     248               60.0 (54--66)   205 (83)      

  NCT02788279\           Yes                   11                          73                   Phase 3        PD-L1         Atezolizumab Cobimetinib                                  840 mg/dose           183               58 (51--67)     107 (58)      Colorectal cancer
  ([@B15])                                                                                                                                                                                                                                                   

                                                                                                               PD-L1         Atezolizumab                                              1,200 mg/dose         90                56 (51--64)     59 (66)       

                                                                                                               Control       Regorafenib                                               /                     90                59 (52--66)     51 (57)       

  NCT02220894\           Yes                   32                          213                  Phase 3        PD-1          Pembrolizumab                                             200 mg/dose           636               63 (56--69)     450 (71)      NSCLC
  ([@B36])                                                                                                                                                                                                                                                   

                                                                                                               Control       Platinum                                                  /                     615               63 (57--69)     452 (71)      

  NCT02613507\           Yes                   3                           32                   Phase 3        PD-1          Nivolumab                                                 3                     338               60 (27--78)     236 (78)      NSCLC
  ([@B71])                                                                                                                                                                                                                                                   

                                                                                                               Control       Docetaxel                                                 /                     166               60 (38--78)     134 (81)      

  NCT02454933\           No                    1                           1                    Phase 3        PD-L1         Durvalumab\                                               10 mg/kg              12                56 (41--78)     6 (50)        NSCLC
  ([@B10])                                                                                                                   Osimertinib                                                                                                                     

                                                                                                               Control       Osimertinib                                               /                     17                65 (41--80)     4 (24)        

  NCT01585987\           Yes                   12                          NR                   Phase 2        CTLA4         Ipilimumab                                                10 mg/kg              57                NR              NR            GEJ　
  ([@B62])                                                                                                                                                                                                                                                   

                                                                                                               Control       Fluoropyrimidine                                          /                     57                NR              NR            

  NCT01984242\           Yes                   9                           NR                   Phase 2        PD-L1         Atezolizumab Bevacizumab                                  1,200 mg/dose         101               NR              74 (73.3)     RCC　
  ([@B54])                                                                                                                                                                                                                                                   

                                                                                                               PD-L1         Atezolizumab                                              1,200 mg/dose         103               NR              77 (74.8)     

                                                                                                               Control       Sunitinib                                                 /                     101               NR              79 (78.2)     

  NCT02367781\           Yes                   36                          NR                   Phase 3        PD-L1         Atezolizumab\                                             1,200 mg/dose         483               NR              NR            NSCLC
  ([@B56])                                                                                                                   Nab-paclitaxel/carboplatin                                                                                                      

                                                                                                               Control       Nab-paclitaxel/carboplatin                                /                     240               NR              NR            

  NCT02352948\           Yes                   NR                          82                   Phase 3 subA   PD-L1         Durvalumab                                                10                    62                NR              42 (67.7)     NSCLC
  ([@B3])                                                                                                                                                                                                                                                    

                                                                                                               PD-L1/CTLA4   Durvalumab\                                               20\                   174               NR              115 (66.1)    
                                                                                                                             Tremelimumab                                              1                                                                     

                         Yes                   NR                          143                  Phase 3 subB   Control       Eerlotinib/gemcitabine/vinorelbine                        /                     64                NR              48 (75.0)     

                                                                                                               PD-L1         Durvalumab                                                10                    117               NR              73 (62.4)     

                                                                                                               CTLA4         Tremelimumab                                              10                    60                NR              39 (65.0)     

                                                                                                               Control       Gemcitabine/vinorelbine                                   /                     118               NR              81 (68.6)     

  NCT02420821\           Yes                   21                          NR                   Phase 3        PD-L1         Atezolizumab Bevacizumab                                  1,200 mg/dose         451               NR              NR            RCC
  ([@B55])                                                                                                                                                                                                                                                   

                                                                                                               Control       Sunitinib                                                 /                     446               NR              NR            

  NCT00094653\           Yes                   13                          125                  Phase 3        CTLA4         Ipilimumab\                                               3                     403               55.6^a^         247 (61.3)    Melanoma
  ([@B23])                                                                                                                   gp100                                                                                                                           

                                                                                                               CTLA4         Ipilimumab                                                3                     137               56.8^a^         81 (59.1)     

                                                                                                               Control       gp100                                                     /                     136               57.4^a^         73 (53.7)     

  NCT00324155 ([@B53])   Yes                   NR                          25                   Phase 3        CTLA4         Ipilimumab Dacarbazine                                    10                    250               57.5^a^         152 (60.8)    Melanoma

                                                                                                               Control       Dacarbazine                                               /                     252               56.4^a^         149 (59.1)    

  ([@B32])               Yes                   NR                          NR                   Phase 2        CTLA4         Ipilimumab\                                               10                    70                NR              NR            NSCLC　
                                                                                                                             Paclitaxel/carboplatin                                                                                                          

                                                                                                               CTLA4         Ipilimumab\                                               10                    68                NR              NR            
                                                                                                                             Paclitaxel/carboplatin                                                                                                          

                                                                                                               Control       Paclitaxel/carboplatin                                    /                     66                NR              NR            

  NCT00257205\           Yes                   24                          114                  Phase 3        CTLA4         Tremelimumab                                              15                    328               57^a^           190 (58)      Melanoma
  ([@B48])                                                                                                                                                                                                                                                   

                                                                                                               Control       Dacarbazine/temozolomide                                  /                     327               56^a^           182 (56)      

  NCT02477826 ([@B21])   Yes                   36                          NR                   Phase 3        PD-1/\        Nivolumab/ipilimumab                                      3\                    396               NR              NR            PD-L1 expression≥1% NSCLC
                                                                                                               CTLA4                                                                   1                                                                     

                                                                                                               PD-1          Nivolumab                                                 240 mg/dose           396               NR              NR            

                                                                                                               Control       Platinum                                                  /                     397               NR              NR            

                                                                                                               PD-1/CTLA4    Nivolumab/ipilimumab                                      3\                    187               NR              NR            PD-L1 expression
                                                                                                                                                                                       1                                                                     

                                                                                                               PD-1          Nivolumab                                                 360 mg/dose           177               NR              NR            \<1% NSCLC　

                                                                                                               Control       Platinum                                                  /                     186               NR              NR            

  NCT02763579 ([@B24])   Yes                   21                          106                  Phase 3        PD-L1         Atezolizumab Carboplatin/etoposide                        1,200 mg/dose         201               64 (28-90)      129 (64.2)    SCLC　

                                                                                                               Control       Carboplatin/etoposide                                     /                     202               64 (26-87)      132 (65.3)    

  NCT02425891 ([@B59])   Yes                   41                          246                  Phase 3        PD-L1         Atezolizumab Nab-paclitaxel                               840 mg/dose           451               55 (20-82)      3 (0.7)       Breast cancer

                                                                                                               Control       Placebo nab-paclitaxel                                    /                     451               56 (26-86)      1 (0.2)       

  NCT02366143 ([@B61])   Yes                   26                          240                  Phase 3        PD-L1         Atezolizumab Bevacizumab/barboplatin/paclitaxel           1,200 mg/dose         400               63 (31-89)      240 (60.0)    NSCLC

                                                                                                               PD-L1         Atezolizumab Carboplatin/paclitaxel                       1,200 mg/dose         402               NR              NR            

                                                                                                               Control       Bevacizumab/carboplatin/paclitaxel                        /                     400               63 (31-90)      239 (59.8)    

  NCT02684006 ([@B38])   Yes                   21                          144                  Phase 3        PD-L1         Avelumab\                                                 10                    442               62 (29-83)      316 (71.5)    RCC
                                                                                                                             Axitinib                                                                                                                        

                                                                                                               Control       Sunitinib                                                 /                     444               61 (27-88)      344 (77.5)    

  NCT02853331 ([@B50])   Yes                   16                          129                  Phase 3        PD-1          Pembrolizumab\                                            200 mg/dose           432               62 (30-89)      308 (71.3)    RCC
                                                                                                                             Axitinib                                                                                                                        

                                                                                                               Control       Sunitinib                                                 /                     429               61 (26-90)      320 (74.6)    

  NCT02250326 ([@B9])    Yes                   7                           34                   Phase 2        PD-L1         Nab-Paclitaxel Durvalumab                                 1,125 mg/m^2^         79                NR              54 (68.4)     NSCLC　

                                                                                                               Control       Nab-paclitaxel                                            /                     80                NR              50 (62.5)     

                                                                                                               Control       Nab-paclitaxel\                                           /                     81                NR              50 (61.7)     
                                                                                                                             CC-486                                                                                                                          

  NCT02924883 ([@B57])   Yes                   9                                                Phase 3        PD-L1         Atezolizumab Trastuzumab/emtansine                        1,200 mg/dose         133               NR              2 (1.5)       Breast cancer

                                                                                                               Control       Placebo\                                                  /                     69                NR              0 (0.0)       
                                                                                                                             Trastuzumab/emtansine                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GEJ, gastric and gastroesophageal junction cancer; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitors; NR, not reported; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; SCLC, small-cell lung cancer. ^a^Age mean.

Quality of the Included Studies {#s3_3}
-------------------------------

[**Table S2**](#SM1){ref-type="supplementary-material"} shows the risk of bias assessment of the included studies for meta-analysis. All studies were RCTs with adequate reported randomization, and all studies were funded by the pharmaceutical industry with a high risk of sponsorship bias. Of the 40 included studies for meta-analysis, 26 (65%) were open labels with a high risk of blinding participants and personnel. None of the included studies specifically stated blinded assessment or collection of diabetes-related adverse events. We classified all trials at unclear risk of incomplete outcome data and selective reporting bias.

Incidence of Diabetes-Related Adverse Events {#s3_4}
--------------------------------------------

Of the 52 clinical controlled trials assessing the effects of ICIs, 40 trials described ICI-associated diabetes events during the course of study. Hyperglycemia events were described in 32 studies; 303 cases of all-grade hyperglycemia and 55 serious-grade hyperglycemia events occurred in 10,393 patients. Pooling the data showed that the rates of all-grade and serious-grade hyperglycemia events were 2.26% (95% CI, 1.28 to 3.48) and 0.28% (95% CI, 0.16 to 0.42), respectively. The rates of hyperglycemia events differed by the type of ICI and tumor. In particular, patients treated with ICI combination therapy were more likely to report hyperglycemia: 3.37% for all-grade hyperglycemia events, 0.47% for serious-grade hyperglycemia. Patients with RCC showed a trend toward higher rates of both all-grade and serious-grade hyperglycemia, with rates of 6.82% and 0.66%, respectively. High dose of ICIs was not associated with high rates of hyperglycemia events ([**Table 2**](#T2){ref-type="table"}).

Due to the smaller number of other ICI-associated diabetes events, no statistical inferences of the rates were made. Overall, 13 cases of DM occurred in 5,655 patients (raw event rate 0.23%), five cases of T2D occurred in 3,117 patients (raw event rate 0.16%), and 17 cases of all-grade T1D occurred in 3,899 patients (raw event rate 0.44%), and 15 cases of serious-grade T1D events occurred in 3,603 patients (raw event rate 0.42%).

###### 

Incidence of hyperglycemia events in patients treated with immune checkpoint inhibitors. Values are percentages (95% confidence intervals).

  Characteristic         All-grade hyperglycemia                   Serious-grade hyperglycemia
  ---------------------- ----------------------------------------- -----------------------------------------
  **Total**              2.26 (1.28, 3.48)                         0.28 (0.16, 0.42)
  **ICI type**                                                     
   PD-1 inhibitors       4.86 (2.86, 7.32)                         0.49 (0.26, 0.78)
   PD-L1 inhibitors      0.81 (0.07, 2.06)                         \\
   CTLA-4 inhibitors     0.52 (0.09, 1.18)                         0.06 (0.00, 0.28)
   Combination therapy   3.37 (0.00, 21.49)                        0.47 (0.00, 2.01)
  **Tumor type**                                                   
   NSCLC                 2.54 (1.10, 4.43)                         0.22 (0.06, 0.45)
   Melanoma              1.75 (0.31, 4.15)                         0.35 (0.09, 0.73)
   RCC                   6.82 (2.00, 14.05)                        0.66 (0.27, 1.18)
   Prostate cancer       0.12[^a^](#fnT2_1){ref-type="table-fn"}   0.12[^a^](#fnT2_1){ref-type="table-fn"}
   Colorectal cancer     0.37[^a^](#fnT2_1){ref-type="table-fn"}   /
   GEJ                   0.57[^a^](#fnT2_1){ref-type="table-fn"}   0.53[^a^](#fnT2_1){ref-type="table-fn"}
   HNSCC                 5.42[^a^](#fnT2_1){ref-type="table-fn"}   0.42[^a^](#fnT2_1){ref-type="table-fn"}
   Mesothelioma          0.52[^a^](#fnT2_1){ref-type="table-fn"}   0.52[^a^](#fnT2_1){ref-type="table-fn"}
   SCLC                  0.63[^a^](#fnT2_1){ref-type="table-fn"}   0.63[^a^](#fnT2_1){ref-type="table-fn"}
  **Dose**                                                         
   High dose             1.33 (0.27, 2.99)                         0.22 (0.00, 0.80)
   Normal dose           2.52 (1.32, 4.03)                         0.28 (0.15, 0.44)

GEJ, gastric and gastroesophageal junction cancer; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; SCLC, small-cell lung cancer.

High doses: including Ipilimumab 10 mg/kg and pembrolizumab 10 mg/kg.

Raw event rate.

Risk of Diabetes-Related Adverse Events {#s3_5}
---------------------------------------

To assess the relative rate of ICI-associated diabetes compared with those in control arms, we calculated the OR of developing diabetes in the RCTs. Pooling the data of these studies showed that patients treated with ICIs were at higher risk for serious-grade hyperglycemia (OR 2.41, 95% CI 1.52 to 3.82, [**Figure 2**](#f2){ref-type="fig"}), DM (OR 3.54, 95% CI 1.32 to 9.51, [**Figure 3**](#f3){ref-type="fig"}), all-grade T1D (OR 6.60, 95% CI 2.51 to 17.30, [**Figure S1**](#SM1){ref-type="supplementary-material"}), and serious-grade T1D (OR 6.50, 95% CI 2.32 to 18.17, [**Figure 4**](#f4){ref-type="fig"}) than those treated with other regimens. ICIs showed a trend toward an increased risk of all-grade hyperglycemia (OR 1.38, 95% CI 1.15 to 1.66, [**Figure S2**](#SM1){ref-type="supplementary-material"}), but no increased risk of T2D (OR 0.92, 95% CI 0.24 to 3.52, [**Figure S3**](#SM1){ref-type="supplementary-material"}). Excluding the study in which the control group was everolimus, a drug known to cause diabetes, the risk of ICI-associated diabetes events were also higher than the control: OR 4.42 for DM, OR 1.75 for all-grade hyperglycemia, OR 2.81 for serious-grade hyperglycemia ([**Figures S4--S6**](#SM1){ref-type="supplementary-material"}).

![Risk of serious-grade hyperglycemia following the use of ICIs versus control treatment, stratified by the type of control group.](fphar-10-01453-g002){#f2}

![Risk of diabetes mellitus following the use of ICIs versus control treatment, stratified by the type of control group.](fphar-10-01453-g003){#f3}

![Risk of serious-grade type 1 diabetes following the use of ICIs versus control treatment, stratified by the type of control group.](fphar-10-01453-g004){#f4}

Subgroup analysis for these outcomes was stratification by the type of control, the mode of treatment, and type of ICI. Regarding the type of control, there were apparent differences across subgroups for the risk of ICI-associated diabetes events. Within the placebo-controlled group, ICIs were associated with a higher risk in hyperglycemia (OR 5.81). Subgroup analysis based on the mode of treatment (monotherapy vs. add-on therapy) suggests that add-on therapy decreased the risk of ICI-associated diabetes, with OR 1.77 for DM, 1.31 for serious-grade hyperglycemia, 0.58 for T2D, and 5.83 for T1D ([**Figures S7--S11**](#SM1){ref-type="supplementary-material"}). The subgroup analysis by the type of ICI suggests the risk of these events was increased in the subset of trials in which anti-PD-1 or anti-PD-L1 was combined with anti-CTLA-4, with OR 7.35 for DM, 2.51 for all-grade hyperglycemia, 4.18 for serious-grade hyperglycemia ([**Figures S12--S17**](#SM1){ref-type="supplementary-material"}).

The funnel plot and statistical test showed no evidence of publication bias for DM (Egger's test *P* = 0.994), all-grade hyperglycemia (Egger's test *P* = 0.128), serious-grade hyperglycemia (Egger's test *P* = 0.325), T2D (Egger's test *P* = 0.310), all-grade T1D (Egger's test *P* = 0.300), and serious-grade T1D (Egger's test *P* = 0.334) ([**Table S3**](#SM1){ref-type="supplementary-material"}, [**Figures S18--S23**](#SM1){ref-type="supplementary-material"}). We noted no heterogeneity in the effects of ICI on DM, serious-grade hyperglycemia, T2D, all-grade T1D, and serious-grade T1D (*I*² = 0.0%). However, we noted substantial heterogeneity for the outcome of all-grade hyperglycemia (*I*² = 88.2%), which was considerably reduced in the analyses of data excluding the everolimus-controlled study (*I*² = 8.0%).

Discussion {#s4}
==========

We completed a systematic analysis of new-onset diabetes following treatment with ICIs versus other therapeutic regimens to further our understanding of the safety of these agents. We used data from 40 RCTs that included 13,787 patients treated with ICIs, and also extracted data from the ClinicalTrials.gov results database to supplement the published studies. To our knowledge, this is the largest and most comprehensive meta-analysis on the incidence and risk of ICI-associated diabetes events following the use of ICI regimens published to date, although previous case series analyses showed that there is an increased reporting of rapidly progressive ICI-associated diabetes ([@B70]; [@B28]; [@B42]). This meta-analysis shows that the risk of serious-grade hyperglycemia, DM, and T1D following ICIs is significantly higher compared with patients treated with other regimens, but provides no support that ICI treatment is associated with an increased risk of all-grade of hyperglycemia. Among patients on each different ICI regimens, patients on combination therapy were more likely to develop hyperglycemia.

Although the incidence was low, T1D has emerged as the highest risk associated with ICI therapy compared with other diabetes-related adverse events. The pathogenesis of T1D in the populations of patients receiving ICIs is not currently well understood. Several case reports have shown that the presence of autoantibodies before ICIs-based therapy might be at risk of developing diabetes, particularly in treated with anti-PD-1/anti-PD-L1 ([@B19]; [@B66]; [@B68]). Further support for autoimmune-based mechanism has been shown by [@B11], who overviewed the reported cases and demonstrated that approximately half of the tested cases of ICI-associated T1D had detectable diabetes-related autoantibodies. Other studies have shown that anti-PD-1 resulted in a rapid progression of autoimmune diabetes in patients with a high underlying genetic predisposition to T1D ([@B34]), raising the concern for genetic factors as a possible mechanism in patients with diabetes-prone HLA genotypes. Similar to what has been described in humans, the study demonstrated that PD-1 or PD-L1 blockade rapidly precipitated diabetes in prediabetic nonobese diabetic (NOD) mice ([@B1]). Taken together, these studies reveal a potential mechanism of ICI-associated T1D that involves in both diabetes-related immunologic and genetic factors.

The subgroup analysis showed that the risk of ICI-associated T1D was different among the different type of ICIs. One possible explanation for this would be the mechanistic link to each target. Unlike the PD-1 pathway, which modulates effector cells, CTLA-4 functions in early immune responses during T cell priming and activation ([@B64]). As such, the distinct function of the PD-1 and CTLA4 potentially contributed to different rates of T1D following the use of ICIs. In NOD mice, CTLA-4 blockade negatively physiologically regulated diabetes in only the early stages of life compared with the PD-1 pathway ([@B1]). Additionally, there was strong PD-L1 expression in the inflamed islets of NOD mice, which suggested that the PD-1-mediated regulation of autoreactive immune cells played an important role at the site of islet inflammation ([@B1]). However, this finding should be interpreted cautiously; more data are needed for definitive conclusions given the low absolute number of T1D in patients receiving ICIs.

ICIs plus conventional treatments have been tested in multiple solid tumors, which achieved synergetic effects and overcame the resistance to immunotherapy ([@B72]). When we combined all non-ICI therapy into one control category, the ICI-based regimens substantially increased the risk of ICI-associated diabetes compared with control group. However, this magnitude was reduced when ICIs were used as an add-on therapy. The risk of DM was 200% lower in the add-on therapy than in the ICI monotherapy. There was also a substantial reduction (over 175%) in ICI-associated serious-grade hyperglycemia in the setting of conventional treatments. These results consistently suggested that compared with ICI therapy, ICIs plus traditional therapy could result in a decreased risk of diabetes-related adverse events.

We found little heterogeneity across studies for all results except hyperglycemia, which strengthens the primary conclusion that ICIs increased risks of diabetes events. A sensitivity analysis identified that everolimus-based control group is responsible for this heterogeneity. Everolimus is an mTOR inhibitor, which is known to influence insulin signaling pathway in peripheral tissues and insulin secretion in *pancreatic* β *cells* ([@B65]). It has described that mTOR inhibitors resulted in a 5-fold increase in the risk for severe hyperglycemia in patients with cancer ([@B67]). Thus, when everolimus was presented separately, the heterogeneity was reduced.

There are several limitations in the present study. We conducted this analysis in study-level, rather than individual patient data. It is not possible to assess potential risk factors that are associated with higher risk of new-onset diabetes, due to the lack of detailed clinical data such as sex, diabetes-prone HLA genotypes, presence of autoantibodies, and islet function in patients receiving ICIs therapy. Secondly, subgroup effects could not be evaluated when there were less than two trials in each subgroup, which could not allow assessing whether the rates of ICI-associated diabetes are varied based on the type of tumor and the dose of ICIs. Our results showed that high dose of ICIs did not contribute to high rates of hyperglycemia events, while the type of tumor showed association of treatment effects. However, regarding other diabetes symptoms, we pooled data across studies together, which might result in the missed difference in dose-dependent and tumor-dependent effect on the risk for these adverse events. Thirdly, whether the increased risk of hyperglycemic events were caused, at least partly, by the use of corticosteroids for the management of irAEs is unclear. Moreover, the results of the present analysis are unable to address potential associations between the incidence of new-onset diabetes and other irAEs in the individual-level. Lastly, only very recent publications have noted T1D after ICI therapy; our study therefore may have underestimated the prevalence of ICI-associated diabetes with only a focus on clinical trials. As emerging case reports that described new-onset diabetes were seen in clinical practice ([@B25]; [@B33]; [@B70]), these adverse events may become more accurately diagnosed and recorded in future trials.

In summary, the use of ICIs compared with placebo or other treatment strategies was associated with an increased risk of new-onset diabetes, especially autoimmune diabetes, although the overall event rates remained low. In contrast, compared with the control group, the risk of T2D was not increased. As the widespread awareness of these events increases, additional large, well-designed randomized trials are needed to definitively determine the risks of new-onset diabetes following the use of ICIs.
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